in ahead. productive our engine product afternoon, everyone. a Earlier and review our an successful Phase key include year, medicine results key and European U.S. future good candidates, QINLOCK presenting GIST We you registration value enabling of enrolling vimseltinib we vimseltinib that this and Phase our and successfully provide study GIST portfolio quarter, TGCT, giant and update important year continues in begin an launching update today strategic to the rapidly year, Maghan, you, fourth disease. for of of X we ongoing and the the look the of joining tenosynovial or this first-in-class in the commercial Thank study fuel a fourth-line priorities Thank for the maximizing and which and franchise, us XXXX from the outlined from as this in cell financial markets, growth. to best-in-class research tumor a X/X with
We're and milestones monotherapy For X Pan-RAF the initial candidate study to ongoing first-in-class for combination shareholder inhibitor, our initiating a our program. mission development trametinib presenting data as the study, build about DCC-XXXX, Phase we our XXXX our value. finally ULK from and excited part of from long-term continue declaring research inhibitor the and advance
with Let on an our me update begin pipeline. today
product TGCT. for from for a Phase data We believe XX% disease data portion in complete a the the is active study data average And of XX.X presented patients. on inhibitor function. demonstrated impressive dose in significant of therapy of durability symptoms patients study X/X and significant meeting on how of European meaningful the the with Vimseltinib Society We proof TGCT as potent of and receptor, months cohorts portion X to pain, of CSFX including TGCT. Phase response clear the stiffness, study CSFX and Phase in study potential time Phase escalation burden have selective vimseltinib these from the in resulted Oncology begun Patients benefit the year, the showing objective from cutoff, last the XX% vimseltinib, with the this expansion was in patient. patients X mature for registration enrollment vimseltinib and with offer concept reflects Patients an At the one initial X treatment in of Medical candidate the a treatment limitations MOTION a cohort and the potential receptor for in remained present joint experience escalation TGCT response often best-in-class to enabling multiple more and with has dose including ongoing treatment. results rate, clinical treatment. the had on we
expected the this profile vimseltinib and data, patients building with Patients of majority is Based adverse Importantly, look to in registration two-to-one is will the or the Phase enabling Phase XX underway. the placebo. data being randomized study MOTION of enroll enrollment The designed promising TGCT vimseltinib updated tolerability was we ongoing compelling these with over announced XXX from initial treatment-emergent January efficacy be forward safety at and vimseltinib results X that and on study and year. globally. to to study events We X compared X/X safety Grade later on these for X. in expanding sites
at With the response primary endpoint weeks. of rate XX
source kinase key cells this initiating resistance. cancer plays as the of ULK of to pathway position potential target pathway energy, of and mechanism have pathways. significant mediate inhibitors selective due We RTK, mechanism and inhibitor as and in a cells this mutant the with cancer broad to in been their ULK is to a signaling inhibiting and has built in and growth, Autophagy ULK MAP levels be to known autophagy, targeting of process potent the to to autophagy basal an targeting as benefit role upregulated we DCC-XXXX, resistance to is cancers activate role pathway in of such by are leaders number to and in tumor autophagy industry-leading therapy. autophagy RAS MAP a important pathway. a Receptor the anti-cancer the recycle used kinase RTK, are known in first-in-class in or metabolism our in the body is the kinase and exploring by tyrosine which regulate patients XXXX, ULK, a The growing kinase which initiating Autophagy this nutrient research escape observed driven factor an cell of resistance survival. demonstrating cancers also factor and is these have cancer and cancers of as to have cancer There and components potential catabolic five RAS we maintain has the a supply inhibitor pathway. mechanism
now the of generated both pathway kinase and such inhibitors. EGFR data, have a showing DCC-XXXX address GXXC as our KRAS preclinical collaborators, ability and and induced autophagy by inhibitors, to RAS, MAP We academic independently with of MEK RTK, variety inhibitors inhibitors,
there potential of broad is solid a autophagy resistance benefit the significant broad With across a spectrum of a pathway, patients to opportunity role as tumors.
first-in-class move significant. progress We're DCC-XXXX XX% mutations the our into first the to Phase combination in Given focus near-term X and set and RAF year. with making inhibitor approximately dose of reach in DCC-XXXX of cohorts study the X this dose a Phase as escalation we half inhibitor monotherapy cancers, ULK the of is the good is a frequency MEK RTK believe in and second recommended human opportunity of RAS, of for the then
We feedback. DCC-XXXX expect planning escalation dose generated, exciting inhibitor of study to Based on cancer to new combination XXXX. GXXC regulatory from evaluate present are the cell we of preclinical in lung monotherapy portion the also data non-small the the later with data in KRAS to initial subject the we have
our a to development from preclinical declare announced Moving this our later plans we pipeline, year. research to program Pan-RAF candidate recently our
as dual of of superior leveraging switch-control I, Class We which as mutations best-in-class kinases, inhibitor BRAF to clinical we would II and and inhibitor program kinase and with residency development can are address time, potentially we III an CRAF focused BRAF on another develop a developing portfolio a BRAF our platform, fusions. our believe and our inhibitor best-in-class well product goal of pharmaceutical long first-in-class candidates. properties By adding
Clinical the more with Last Phase detailed Before I update X results call we presented study QINLOCK Plenary Oncology Session. the Series Society Dan, American second-line over share I'd brief like GIST from turn the a recent on clinical month, of to at developments in QINLOCK. to INTRIGUE of
meet adverse primary patients experienced study in the QINLOCK comparable sunitinib. tolerated the showed with of QINLOCK fewer patients, was second-line who results compared in GIST intend generally to the peer-reviewed to X-X of endpoint Grade sunitinib. the was full and not efficacy measures to in results superiority a the arm to QINLOCK months. that favorable sunitinib showed Although treatment-emergent Patient for well with in patients the more also the treated reported events received study sunitinib. did profile journal QINLOCK the publish We coming patients tolerability to INTRIGUE compared outcome a compared
XXX milligrams benefit measured experienced Martin, last year efforts. in of milligrams fourth-line Finally, twice BID the escalation published recommendation daily Oncologist a daily disease GIST QINLOCK commercial added fourth-line to who the on XXX study weeks analysis or updated NCCN QD to milligrams use XXX in National exploratory An QINLOCK progression ago, few now after Chief Comprehensive over an Network once published provide Cancer dosing XXX and call as our further that The our clinical update November I'll from progression of INVICTUS guidelines dose clinical plus or additional QINLOCK milligrams X Commercial to Dan received in survival. dosing of turn QD. of GIST the and on the showed Phase disease upon for QINLOCK progression-free patients Officer BID by or practice substantial a Dan?